Eli Lilly, Immunocore Partner in Immunotherapy
Eli Lilly and Company and
The deal centers around Immunocore’s Immune Mobilizing Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, which has shown potential to direct a patient’s T cells to specifically target cancerous cells, thereby avoiding damage to healthy cells. Under the agreement, Immunocore will receive an upfront fee of
T Cell Receptors naturally recognize diseased cells and Immunocore’s competitive position is its ability to engineer high-affinity T Cell Receptors and link them to an antibody fragment that can activate the immune system to kill the targeted cancer or viral cells. These bi-specific proteins, called ImmTACS, have the potential to be potent anti-cancer or antiviral agents. The most advanced ImmTAC is in Phase II clinical trials for the treatment of late-stage melanoma.
Immunocore, based in Abingdon,
Source: Eli Lilly .